These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 22932872)

  • 1. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43.
    Wang IF; Guo BS; Liu YC; Wu CC; Yang CH; Tsai KJ; Shen CK
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15024-9. PubMed ID: 22932872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy activation ameliorates neuronal pathogenesis of FTLD-U mice: a new light for treatment of TARDBP/TDP-43 proteinopathies.
    Wang IF; Tsai KJ; Shen CK
    Autophagy; 2013 Feb; 9(2):239-40. PubMed ID: 23108236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
    Lee S; Jeon YM; Cha SJ; Kim S; Kwon Y; Jo M; Jang YN; Lee S; Kim J; Kim SR; Lee KJ; Lee SB; Kim K; Kim HJ
    Autophagy; 2020 Aug; 16(8):1396-1412. PubMed ID: 31690171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS.
    Chang CF; Lee YC; Lee KH; Lin HC; Chen CL; Shen CJ; Huang CC
    J Biomed Sci; 2016 Oct; 23(1):72. PubMed ID: 27769241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin and chloroquine: the in vitro and in vivo effects of autophagy-modifying drugs show promising results in valosin containing protein multisystem proteinopathy.
    Nalbandian A; Llewellyn KJ; Nguyen C; Yazdi PG; Kimonis VE
    PLoS One; 2015; 10(4):e0122888. PubMed ID: 25884947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP.
    Cheng CW; Lin MJ; Shen CK
    J Neurogenet; 2015; 29(2-3):59-68. PubMed ID: 26219309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U.
    Tsai KJ; Yang CH; Fang YH; Cho KH; Chien WL; Wang WT; Wu TW; Lin CP; Fu WM; Shen CK
    J Exp Med; 2010 Aug; 207(8):1661-73. PubMed ID: 20660618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transthyretin attenuates TDP-43 proteinopathy by autophagy activation via ATF4 in FTLD-TDP.
    Chu YP; Jin LW; Wang LC; Ho PC; Wei WY; Tsai KJ
    Brain; 2023 May; 146(5):2089-2106. PubMed ID: 36355566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [FTLD/ALS as TDP-43 proteinopathies].
    Ishihara T; Ariizumi Y; Shiga A; Yokoseki A; Sato T; Toyoshima Y; Kakita A; Takahashi H; Nishizawa M; Onodera O
    Rinsho Shinkeigaku; 2010 Nov; 50(11):1022-4. PubMed ID: 21921552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible behavioral phenotypes in a conditional mouse model of TDP-43 proteinopathies.
    Alfieri JA; Pino NS; Igaz LM
    J Neurosci; 2014 Nov; 34(46):15244-59. PubMed ID: 25392493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [TDP-43 proteinopathies, toward understanding of the molecular pathogenesis].
    Hasegawa M; Nonaka T; Yamashita M; Kametani F; Arai T; Yoshida M; Hashizume Y; Tsuchiya K; Akiyama H
    Rinsho Shinkeigaku; 2009 Nov; 49(11):783-5. PubMed ID: 20030209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC1 dysregulation induces aberrant cell cycle and DNA damage in progress of TDP-43 proteinopathies.
    Wu CC; Jin LW; Wang IF; Wei WY; Ho PC; Liu YC; Tsai KJ
    EMBO Mol Med; 2020 Jun; 12(6):e10622. PubMed ID: 32449313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stathmin-2: adding another piece to the puzzle of TDP-43 proteinopathies and neurodegeneration.
    Glass JD
    J Clin Invest; 2020 Nov; 130(11):5677-5680. PubMed ID: 33074248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability.
    Caccamo A; Majumder S; Deng JJ; Bai Y; Thornton FB; Oddo S
    J Biol Chem; 2009 Oct; 284(40):27416-24. PubMed ID: 19651785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withaferin-A Treatment Alleviates TAR DNA-Binding Protein-43 Pathology and Improves Cognitive Function in a Mouse Model of FTLD.
    Kumar S; Phaneuf D; Julien JP
    Neurotherapeutics; 2021 Jan; 18(1):286-296. PubMed ID: 33078279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and mis-metabolism of the neuropathological signature protein TDP-43.
    Huang CC; Bose JK; Majumder P; Lee KH; Huang JT; Huang JK; Shen CK
    J Cell Sci; 2014 Jul; 127(Pt 14):3024-38. PubMed ID: 24860144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sqstm1 knock-down causes a locomotor phenotype ameliorated by rapamycin in a zebrafish model of ALS/FTLD.
    Lattante S; de Calbiac H; Le Ber I; Brice A; Ciura S; Kabashi E
    Hum Mol Genet; 2015 Mar; 24(6):1682-90. PubMed ID: 25410659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TDP-43 loss of function increases TFEB activity and blocks autophagosome-lysosome fusion.
    Xia Q; Wang H; Hao Z; Fu C; Hu Q; Gao F; Ren H; Chen D; Han J; Ying Z; Wang G
    EMBO J; 2016 Jan; 35(2):121-42. PubMed ID: 26702100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALS and FTLD: two faces of TDP-43 proteinopathy.
    Liscic RM; Grinberg LT; Zidar J; Gitcho MA; Cairns NJ
    Eur J Neurol; 2008 Aug; 15(8):772-80. PubMed ID: 18684309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
    Zhang X; Li L; Chen S; Yang D; Wang Y; Zhang X; Wang Z; Le W
    Autophagy; 2011 Apr; 7(4):412-25. PubMed ID: 21193837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.